Bayer’s ASSESS study is a randomised, double-blind, placebo-controlled, parallel group phase 2a trial with an extension phase ...
Johnson & Johnson has received European Commission approval for nipocalimab, marketed as IMAAVY, as an add-on therapy for ...
Pharvaris has announced positive topline data from its RAPIDe-3 pivotal phase 3 study, confirming the potential of ...
The phase 1 trial, VNA-318-01, was a randomized, double-blind study involving 92 healthy male subjects. Interim results ...
Young people are our future workforce, so it’s important that companies have a youth-positive culture. To be competitive, ...
SERB Pharmaceuticals has appointed Dr Vignesh Rajah as its new Chief Medical Officer, bringing over 20 years of global ...
Draig Therapeutics has announced the appointment of Ivana Magovčević-Liebisch as President and Chief Executive Officer. She ...
AlzeCure Pharma AB has announced it has received the first payment of a EUR 2.5 million grant from the European Innovation Council (EIC). The funding will support a phase 2a clinical study of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback